Beranda › Dermatomiositis
Uji klinis Dermatomiositis yang merekrut di AS
26 studi untuk Dermatomiositis merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Durham, NC8 studi
- Washington, DC7 studi
- New York City, NY5 studi
- Pittsburgh, PA5 studi
- Houston, TX5 studi
- Boston, MA5 studi
- Baltimore, MD4 studi
- Philadelphia, PA4 studi
- Miami, FL4 studi
- Aurora, CO3 studi
- Phoenix, AZ3 studi
- Kansas City, KS3 studi
- Jacksonville, FL3 studi
- Cleveland, OH3 studi
- New Haven, CT3 studi
Berdasarkan negara bagian
- Arizona4 studi
- California9 studi
- Colorado4 studi
- Connecticut3 studi
- Florida7 studi
- Illinois3 studi
- Kansas4 studi
- Maryland9 studi
- Massachusetts5 studi
- New York6 studi
- North Carolina8 studi
- Ohio5 studi
- Pennsylvania7 studi
- Texas6 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Menerima pesertaFase 2
Usia 18 hingga 60 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07111065Environmental Risk Factors for the Anti-synthetase Syndrome
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 2 hingga 100 · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT01276470Natural History of Inflammatory Muscle Diseases
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 2 hingga 120 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05738824Adult and Juvenile Myositis
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 2 hingga 100 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT00017914A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06455449Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT03816345RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Menerima pesertaFase 2/3
Usia 6 hingga 75 · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06154252A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Menerima pesertaFase 1
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT06916806A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT05895786A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Menerima pesertaFase 1
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07085104FT839 in Autoimmune Diseases
Menerima pesertaFase 1/2
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07800871Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT07486869A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT06698796Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
Menerima pesertaFase 1/2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT07089121Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Menerima pesertaFase 1
Usia 18 hingga 85 · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT06371417A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Jul 2026 · NCT07115745Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Jul 2026 · NCT07138898Intralesional Injection of STS in Treatment of Calcinosis
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06672822Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Apr 2026 · NCT07160205Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Mar 2026 · NCT02945345Rheumatology Patient Registry and Biorepository
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT04402086A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Feb 2026 · NCT07403188MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
Menerima pesertaStudi observasional
Usia 7 ke atas · Semua jenis kelamin · Diperbarui 28 Jan 2026 · NCT07374107Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis
Menerima pesertaFase 2
Usia 18 hingga 89 · Semua jenis kelamin · Diperbarui 8 Okt 2025 · NCT06857240Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis
Menerima pesertaFase 1
Usia 25 hingga 72 · Semua jenis kelamin · Diperbarui 21 Mei 2025 · NCT06298019Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.